stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) EBITDA
Tango Therapeutics, Inc.'s EBITDA for fiscal 2025 was −$111.7M, compared with −$147.7M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$137.8M. Over the past ten years it has ranged from −$147.7M (fiscal 2024) to −$51.5M (fiscal 2020); the current reading is higher than 50% of that period. Tango Therapeutics, Inc. ranks 459th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$111.7M | — |
| FY2024 | −$147.7M | — |
| FY2023 | −$115.2M | — |
| FY2022 | −$109.5M | — |
| FY2021 | −$57.3M | — |
| FY2020 | −$51.5M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$60.3M | — |
| Mar 2026 | −$49.4M | — |
| Dec 2025 | −$42.2M | — |
| Sep 2025 | $14.1M | — |
| 21 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $96.1M |
| TNGX Tango Therapeutics, Inc. | −$137.8M |
| PBLS Parabilis Medicines, Inc. compare | −$172.4M |
| ABCL AbCellera Biologics Inc. compare | −$192.6M |
| EWTX Edgewise Therapeutics, Inc. compare | −$221.9M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$261.9M |
| IRON Disc Medicine, Inc. compare | −$273.8M |
| RLAY Relay Therapeutics, Inc. compare | −$311.6M |
| XENE Xenon Pharmaceuticals Inc. compare | −$439.2M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement